As previously reported, Wolfe Research upgraded Immunovant (IMVT) to Outperform from Peer Perform with a $50 price target. While Graves’ may be an attractive market, the firm had believed re-rating would take years. However, with Argenx (ARGX) now participating in Graves’ and thus investors developing higher appreciation, there likely is now a higher valuation floor to Immunovant, the analyst contends. The firm sees the declining short float as supporting evidence for this and notes that the company is moving closer to two positively-skewed catalysts in 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- Immunovant upgraded to Outperform from Peer Perform at Wolfe Research
- Immunovant price target lowered to $41 from $44 at Guggenheim
- Immunovant Raises $550 Million Through Stock Offering
- Immunovant’s Strategic Advancements and Promising Pipeline Drive Buy Rating
- Immunovant Announces $550 Million Stock Offering